| Tuesday, November 4, 2008 | ||
| 13:30:00 | EASING OF SUFFERING IN CHILDREN WITH ADVANCED CANCER | Joanne Wolfe |
| 13:45:00 | HEMATOPOIETIC CELL TRANSPLANTATION IN AML | Elizabeth , Roman |
| 14:00:00 | UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION | Vinod K. Prasad |
| 14:15:00 | JMML: DIAGNOSTIC AND TREATMENT CONSIDERATIONS | Todd Cooper |
| 14:30:00 | NEW TRENDS IN PEDIATRIC HODGKIN'S LYMPHOMA | Richard A. Drachtman |
| 14:45:00 | PEDIATRIC NON-HODGKIN'S LYMPHOMA | Stan C. Goldman |
| 15:00:00 | Coffee Time | |
| 15:15:00 | CURRENT CLINICAL TRIAL FOR RHABDOMYOSARCOMA | Douglas Hawkins |
| 15:30:00 | LIMB-SPARING SURGERY FOR BONE SARCOMAS | James C. Wittig |
| 15:45:00 | CHEMOTHERAPY FOR CHILDHOOD MALIGNANT BRAIN TUMORS | James H. Garvin |
| 16:00:00 | SIMULTANEOUS INTERRUPTION OF METABOLIC PATHWAYS IN CHILDHOOD ALL | Julio C. Barredo |
| 16:15:00 | ADVANCES IN TREATMENT STRATEGIES IN PEDIATRIC ALL | Stephen E. , Sallan |
| 16:30:00 | Discussion | |
| 19:00:00 | MEETING THE CLINICAL TRIAL CHALLENGES EMERGING FROM NOVEL BIOLOGICAL PLATFORMS | Robert J Arceci |
| 19:00:00 | PROGRESS IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA | Paul S. Gaynon |
| 19:00:00 | DINNER AND SPECIAL PRESENTATION | |
| Wednesday, November 5, 2008 | ||
| 07:00:00 | DINNER AND PRESENTATIONS | |
| 07:00:00 | BREAKFAST WITH THE PROFESSORS | |
| 07:00:00 | AN UPDATE OF ESAs IN ONCOLOGY | Jeffrey Crawford |
| 07:00:00 | CHEMOTHERAPY INDUCED THROMBOCYTOPENIA: NEW DEVELOPMENTS IN PATHOPHYSIOLOGY AND TREATMENT | James B. Bussel |
| 08:00:00 | MYELOPROLIFERATIVE/MYELODYSPLASTIC DISORDERS New Approaches and New Agents | |
| 08:00:00 | WELCOME | Edward P. Ambinder, Janice L. Gabrilove, Steven J. Burakoff |
| 08:00:00 | MORNING SESSION | |
| 08:00:00 | HEMATOLOGIC MALIGNANCIES | George F. Atweh, Janet Cuttner, Janice L. Gabrilove |
| 08:10:00 | MOLECULAR CHARACTERIZATION AND THERAPEUTIC TARGETS IN MPD | Ronald Hoffman |
| 08:25:00 | JAK2 and MPL MUTATIONS | Richard T. Silver |
| 08:40:00 | EPIGENETIC THERAPY IN MDS | Hagop Kantarjian |
| 08:55:00 | VORELOXIN (SNS-595): AN ACTIVE AGENT IN AML | Gail J. Roboz |
| 09:10:00 | THERAPY FOR POST-IMATINIB FAILURES | Jorge E. Cortes |
| 09:25:00 | APPROACH TO FRONT-LINE THERAPY IN CLL | |
| 09:40:00 | LENALIDOMIDE AND RITUXIMAB IN CLL | |
| 09:55:00 | FLAVOPIRODOL IN CLL | Janice L. , Gabrilove |
| 10:10:00 | Coffee Time | |
| 10:40:00 | LUMILIXIMAB STUDIES IN CLL | Susan O’Brien |
| 10:50:00 | UPDATE on IMIDS in NHL | Myron Czuczman |
| 11:00:00 | TARGETED THERAPY FOR DIFFUSE LARGE B-CELL LYMPHOMAS | Ari M. Melnick |
| 11:15:00 | BORTEZOMIB AND LENALIDOMIDE-BASED TRIALS | Sundar Jagannath |
| 11:30:00 | CARFILZOMIB: A NOVEL PROTEASOME INHIBITOR IN MYELOMA AND OTHER MALIGNANCIES | Howard A. Burris |
| 11:45:00 | Discussion | |
| 12:00:00 | Role of Transplantation | William Bensinger |
| 12:00:00 | LUNCH AND PRESENTATIONS | |
| 12:00:00 | Practical Applications of Clinical Trial Data | Rav , Vij |
| 12:00:00 | NEW DEVELOPMENTS IN MULTIPLE MYELOMA | |
| 12:00:00 | AFTERNOON SESSION | |
| 13:15:00 | DILEMMAS IN ADJUVANT THERAPY FOR EARLY BREAST CANCER: THE NSABP EXPERIENCE | Norman Wolmark |
| 13:15:00 | GI CANCERS | Jordan Berlin |
| 13:15:00 | KEYNOTE ADDRESS | |
| 13:35:00 | MODIFIED DOCETAXEL-BASED REGIMENS FOR ADVANCED GASTROESOPHAGEAL CANCERS | Jaffer , Ajani |
| 13:50:00 | BIOMARKERS IN DECISION MAKING STAGE II COLON CANCER | Anthony B. El-Khoueiry |
| 14:00:00 | NEW TYROSINE KINASE INHIBITORS FOR METASTATIC COLORECTAL CANCER | Paulo M. Hoff |
| 14:15:00 | CAN CIRCULATING TUMOR CELLS BE A PREDICTIVE MARKER FOR TREATMENT OF COLON CANCER? | Neal J. Meropol |
| 14:25:00 | SONIC HEDGEHOG: A NEW TARGET IN COLORECTAL CANCER? | |
| 14:40:00 | NEW PARADIGMS IN TREATMENT OF OXALIPLATIN NEUROTOXICITY | Howard S. Hochster |
| 14:50:00 | REDUCING RISK OF RECURRENT COLON POLYPS | Eugene W. Gerner |
| 15:00:00 | Coffee Time | |
| 15:30:00 | MELPHALAN IN NON-COLORECTAL METASTASES TO THE LIVER | James , Pingpank |
| 15:40:00 | HEATED INTRAPERITONEAL CHEMOTHERAPY (HIPEC) IN METASTATIC GI MALIGNANCY | Daniel M. , Labow |
| 15:50:00 | PERSPECTIVES ON HIPEC THERAPY | Elliot Newman |
| 16:00:00 | PANCREATIC CANCER: WHERE ARE WE GOING? | Jordan Berlin |
| 16:15:00 | PHARMACOGENOMICS IN CANCER CLINICAL TRIALS | Craig C. , Lockhart |
| 16:30:00 | SMALL CELL CARCINOMA OF THE GI TRACT | Heine Hansen |
| 16:45:00 | Discussion | |
| 19:00:00 | THERAPY OPTIONS FOR RITUXIMAB-REFRACTORY INDOLENT NHL | John P. Leonard |
| 19:00:00 | BENDAMUSTINE AND OTHER TARGETED AGENTS IN NHL | Ann S. LaCasce |
| 21:00:00 | End of the day | |
| Thursday, November 6, 2008 | ||
| 07:00:00 | MORNING SESSION | Franco M. Muggia, Carmel Cohen |
| 07:00:00 | GYNECOLOGICAL CANCERS | |
| 07:00:00 | TARGETING VEGF RECEPTORS WITH PAZOPANIB: BIOLOGIC RATIONALE AND EMERGING CLINICAL DATA | |
| 07:00:00 | LAPATINIB: PREVENTING METASTATIC COLONIZATION OF BC CELLS IN THE BRAIN | Diane , Palmieri |
| 07:00:00 | BREAKFAST WITH THE PROFESSORS | |
| 08:00:00 | INTRAPERITONEAL THERAPY FOR OVARIAN CANCER: MISSION ACCOMPLISHED? | Franco M. Muggia |
| 08:15:00 | CISPLATIN RESISTANT OVARIAN CANCER: OXALIPLATIN OR PACLITAXEL? | Britta Stordal |
| 08:30:00 | VORELOXIN (SNS-595) IN PLATINUM-RESISTANT OVARIAN CANCER | William P. McGuire |
| 08:45:00 | NOVEL INTRAPERITONEAL STRATEGIES FOR MANAGING PLATINUM RESISTANCE | Stephen B. Howell |
| 09:00:00 | TRABECTEDIN IN RECURRENT OVARIAN CANCER | Bradley J Monk |
| 09:15:00 | NATIONAL AND INTERNATIONAL TRIALS IN OVARIAN CANCER | William P. McGuire |
| 09:30:00 | HARNESSING THE IMMUNE SYSTEM FOR OVARIAN CANCER THERAPY | Kunle Odunsi |
| 09:45:00 | EXPLOITING GENETIC DEFECTS WITH POLYMERASE INHIBITORS | Hilary Calvert |
| 10:00:00 | Discussion | |
| 10:15:00 | BRAIN | |
| 10:15:00 | Coffee Time | |
| 10:45:00 | UPDATE: PHASE II TRIAL OF CEDIRANIB IN RECURRENT GLIOBLASTOMA | Elizabeth R. Gerstner |
| 11:00:00 | NEUROENDOCRINE | |
| 11:00:00 | ATIPRIMOD PHASE II TRIAL FOR NEUROENDOCRINE CANCER | Max W. , Sung |
| 11:15:00 | ORAL DEFOROLIMUS IN METASTATIC SOFT-TISSUE AND BONE SARCOMAS | |
| 11:15:00 | SARCOMA | |
| 11:30:00 | INTRAVENOUS REOLYSIN IN BONE OR SOFT TISSUE SARCOMA METASTIC TO LUNG | Monica M. Mita |
| 11:45:00 | Discussion | |
| 12:00:00 | ADVANCES IN HCC THERAPY | Josep M. Llovet |
| 12:00:00 | BREAST CANCER | |
| 12:00:00 | AFTERNOON SESSION | |
| 12:00:00 | OVERVIEW OF ASIAN DATA ON HCC | Bert H. O'Neil |
| 12:00:00 | LUNCH AND PRESENTATIONS | |
| 13:30:00 | EZRA M. GREENSPAN MEMORIAL LECTURE | |
| 13:30:00 | INNOVATIVE STRATEGIES FOR DRUG DEVELOPMENT | Howard A. Burris |
| 13:50:00 | THE SELF-SEEDING MODEL OF CANCER: CLINICAL IMPLICATIONS | Larry Norton |
| 14:05:00 | NEW ASSAYS TO DETERMINE HER2 STATUS | Allan Lipton |
| 14:20:00 | FULVESTRANT: WHAT HAVE WE LEARNED FROM USING HIGHER DOSES? | Irene Kuter |
| 14:35:00 | COMBINED ANTI-HER2 THERAPY: TRASTUZUMAB AND LAPATINIB | Harold J. Burstein |
| 14:50:00 | TRASTUZUMAB-DM1, A NOVEL APPROACH TO THE TREATMENT OF HER2+ BREAST CANCER | Ian E. Krop |
| 15:05:00 | Coffee Time | |
| 15:35:00 | LAPULEUCEL-T IN IMMUNOTHERAPY OF BREAST CANCER: CLINICAL TRIAL DATA | John Park |
| 15:50:00 | HER2 VACCINATION IN HIGH RISK BREAST CANCER | George E. , Peoples |
| 16:05:00 | PROTEASOME INHIBITOR ENHANCES HORMONAL THERAPY IN BREAST CANCER | Samuel , Waxman |
| 16:20:00 | Discussion | |
| 16:20:00 | THYROID | |
| 16:35:00 | TREATMENT OF IODINE-RESISTANT ADVANCED THYROID CANCER | Marcia S. Brose |
| 16:45:00 | HEAD AND NECK | |
| 16:45:00 | OVERCOMING IMMUNOSUPPRESSION IN HEAD AND NECK CANCER WITH CITOPLURIKIN (IRX-2) | Jeffrey S. Moyer |
| 16:55:00 | Discussion | |
| 19:00:00 | PERSONALIZED MEDICINE: TREATMENT DECISION-MAKING | Norman Wolmark |
| 19:00:00 | DINNER AND PRESENTATIONS | |
| 21:00:00 | End of the day | |
| Friday, November 7, 2008 | ||
| 07:00:00 | BREAKFAST WITH THE PROFESSORS | |
| 07:00:00 | THE CONTROVERSY: ARE ANTHRACYCLINES NECESSARY FOR EARLY BREAST CANCER? | Stephen E. Jones |
| 07:00:00 | UPDATE ON CHEMOTHERAPY FOR ADVANCED BREAST CANCER | Stephen Y. Chan |
| 07:00:00 | MORNING SESSION | |
| 07:00:00 | URO-ONCOLOGY | |
| 08:00:00 | ENDOTHELIAL A: SURVIVAL AND BONE METASTASES IN HRPC | Nancy A. Dawson |
| 08:00:00 | PROSTATE | |
| 08:15:00 | VACCINE APPROACHES IN EARLY STAGE PC | Robert S. DiPaola |
| 08:30:00 | ABIRATERONE ACETATE: AN ANDROGEN WITHDRAWAL RESPONSIVE PHENOTYPE IN CRPC | Eleni Efstathiou |
| 08:45:00 | DEVELOPING COMBINATION STRATEGIES WITH HISTONE DEACETYLASE INHIBITORS | |
| 08:45:00 | RENAL | |
| 08:45:00 | DEVELOPING COMBINATION STRATEGIES WITH HISTONE DEACETYLASE INHIBITORS | Roberto , Pili |
| 08:55:00 | PHARMACODYNAMIC TRIAL OF FLT-PET/CT IMAGING IN SUNITINIB-TREATED RENAL CELL CARCINOMA | Glenn Liu |
| 09:10:00 | Discussion | |
| 09:10:00 | Discussion | |
| 09:10:00 | LUNG CANCER | |
| 09:25:00 | ROLE OF MAINTENANCE THERAPY IN ADVANCED NSCLC | Chandra P. Belani |
| 09:40:00 | EGFR INHIBITORS IN NSCLC AND HOW TO SELECT PATIENTS | Fred R. Hirsch |
| 09:55:00 | EVOLVING ROLE OF SUNITINIB IN NSCLC | Mark A. Socinski |
| 10:05:00 | Coffee Time | |
| 10:20:00 | TALACTOFERRIN IN REFRACTORY NSCLC | Giuseppe Giaccone |
| 10:30:00 | PERSONALIZED THERAPY APPROACHES FOR ADVANCED NSCLC | Roy S. Herbst |
| 10:45:00 | THIRD LINE THERAPY FOR NSCLC AND BEYOND | Cory , Langer |
| 11:00:00 | PHASE II STUDY OF PICOPLATIN FOR 2ND LINE SCLC | John R. , Eckhardt |
| 11:10:00 | UPDATE ON AMRUBICIN IN SCLC | Robert M. Jotte |
| 11:20:00 | PHASE I/II STUDY OF DOCETAXEL PLUS OBATOCLAX (GX17-070) IN RELAPSED NSCLC | Alberto A. Chiappori |
| 11:30:00 | MAG3 VACCINATION FOR LUNG CANCER | Nasser Altorki |
| 11:40:00 | LUNG CANCER VACCINE L-BLP25 | Nevin Murray |
| 11:50:00 | Discussion | |
| 12:00:00 | ASA-404: A NOVEL VASCULAR DISRUPTING AGENT FOR LUNG CANCER THERAPY | Primo Jr. N. Lara |
| 12:00:00 | EVEROLIMUS FOR RENAL CELL CARCINOMA | Robert J. Motzer |
| 12:00:00 | LUNCH AND PRESENTATIONS | |
| 13:15:00 | AFTERNOON SESSION | |
| 13:15:00 | DIVERSE THERAPEUTICS | |
| 13:15:00 | JUDAH FOLKMAN MEMORIAL LECTURE | |
| 13:15:00 | IMMUNE THERAPY FOR OVARIAN CANCER: ARE WE READY TO LAUNCH? | George Coukos |
| 13:35:00 | MELANOMA | |
| 13:35:00 | STAGING AND PROGNOSTIC CRITERIA | Charles M. Balch |
| 13:50:00 | SYSTEMIC ADH-1 AND MEPHALAN ILI IN ADVANCED EXTREMITY | Douglas S. Tyler |
| 14:05:00 | THE EVOLUTION OF OBLIMERSEN | Anna Pavlick |
| 14:15:00 | RADIOTHERAPY WITH IMMUNOTHERAPY | Silvia C. Formenti |
| 14:15:00 | IMMUNOTHERAPY | |
| 14:25:00 | NOVEL ANTICANCER AGENTS IN THE NCI CTEP CLINICAL DEVELOPMENT PROGRAM | John J. Wright |
| 14:25:00 | SOLID TUMORS | |
| 14:40:00 | AMG386: A FIRST-IN-CLASS ANGIOPOIETIN TARGETED THERAPY | Alain C. Mita |
| 14:50:00 | TERAMEPROCOL INFUSION FOR REFRACTORY SOLID TUMORS | Jeffrey Infante |
| 15:00:00 | Coffee Time | |
| 15:15:00 | ENILURACIL: CLINICAL UPDATE ON NOVEL SCHEDULES WITH A DPD-INHIBITOR | Howard A. Burris |
| 15:25:00 | EVALUATION OF MLN 8237: A NOVEL AURORA A KINASE INHIBITOR | E. Claire Dees |
| 15:25:00 | OTHER CLINICAL OPTIONS | |
| 15:35:00 | RECENT DATA FROM THE Z-FAST AND ZO-FAST TRIALS | Allan Lipton |
| 15:45:00 | AERODIGESTIVE CANCER PREVENTION | Alex A Adjei |
| 16:00:00 | GENERIC TREATMENT PLAN TEMPLATE | Joseph Jacobson |
| 16:15:00 | LATE BREAKING DEVELOPMENTS | |
| 16:45:00 | Discussion | |
| 19:00:00 | DINNER AND PRESENTATIONS | |
| 19:00:00 | CHANGING PARADIGMS IN THE THERAPEUTIC APPROACH TO ADVANCED NSCLC | Mark A. Socinski |
| 19:00:00 | CETUXIMAB IN NSCLC | Thomas J. Lynch |
| 21:00:00 | End of the day | |
| Saturday, November 8, 2008 | ||
| 06:55:00 | NEW PERSPECTIVES IN ONCOLOGY PRACTICE | |
| 07:00:00 | Registration & Continental Breakfast | |
| 08:00:00 | OPENING REMARKS | Shannon B. , Holloway, Andrea Downey |
| 08:10:00 | NOVEL THERAPEUTICS FOR MELANOMA | Anna Pavlick |
| 08:30:00 | WHEN YOUR PATIENT DIES: PERSONAL GRIEF IN THE PROFESSIONAL SETTING | Nora , Rightmer |
| 08:50:00 | MYELODYSPLATIC SYNDROME: SUPPORTIVE CARE TO ACTIVE TREATMENT | Sandra L. Allen-Bard |
| 09:10:00 | MAKING THE LAW WORK FOR YOU AND YOUR PATIENT: DOCUMENTING & PRESCRIBING CONTROLLED SUBSTANCES | Jennifer Bolen |
| 09:35:00 | NEW ADVANCES IN mTor THERAPY | Andrea Rustine |
| 09:55:00 | CHEMOBRAIN & COGNITIVE FUNCTION | Lynne I. Wagner |
| 10:15:00 | BREAK | |
| 10:35:00 | KEYNOTE ADDRESS | |
| 10:35:00 | DEALING WITH EMOTIONS, STRENGTHENING RELATIONSHIPS | Robert A. , Buckman |
| 11:05:00 | THE CHANGING PRACTICE MANAGEMENT ENVIRONMENT | Joseph S. Bailes |
| 11:25:00 | TRANSPLANT-RELATED INFECTIONS: THE CHALLENGE CONTINUES | Angela Johns |
| 11:45:00 | USE OF METHADONE IN CANCER TREATMENT | Nessa Coyle |
| 12:05:00 | LUNCH | |
| 13:15:00 | VIDEO: CANCER THROUGH THE EYES OF THE PATIENT AND FAMILY | Teresa Gilewski |
| 13:40:00 | PATIENT-CENTRIC QUALITY ONCOLOGY CARE | Edward P. Ambinder |
| 14:00:00 | EMERGING TRENDS IN MULTIPLE MYELOMA TREATMENT | Faiza Zafar |
| 14:20:00 | PALLIATIVE INTERVENTIONS IN THE ONCOLOGY WORLD | Christopher , Comfort |
| 14:40:00 | ADHERENCE TO THERAPY: IT MAY BE A BIGGER ISSUE THAN YOU REALIZE | Cathy Maxwell, |
| 15:00:00 | TRENDS IN THE MANAGEMENT OF COLORECTAL CANCER | Shannon B. , Holloway |
| 15:40:00 | EMERGING TRENDS IN THE MANAGEMENT OF VTE IN CANCER PATIENTS | EDITH A. NUTESCU |
| 16:00:00 | CLOSING REMARKS | Shannon B. , Holloway, Andrea Downey |
| 16:00:00 | End of the day | |
How We Rank